| Drug General Information |
| Drug ID |
D06XTT
|
| Former ID |
DIB019870
|
| Drug Name |
FPL64176
|
| Synonyms |
FPL-64176; FPL 64176
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
|
| Formula |
C22H21NO3
|
| InChI |
InChI=1S/C22H21NO3/c1-14-19(20(15(2)23-14)22(25)26-3)21(24)18-12-8-7-11-17(18)13-16-9-5-4-6-10-16/h4-12,23H,13H2,1-3H3
|
| InChIKey |
MDMWHKZANMNXTF-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
586345, 5643537, 8152178, 11111167, 11114067, 14851813, 17405111, 24277836, 24711524, 26752183, 26752184, 29222557, 46500442, 47440485, 47440486, 49635711, 49738154, 50070487, 50071129, 50104840, 50104841, 50104842, 53777654, 57321791, 78756040, 85086231, 85231042, 85788737, 87350894, 90341572, 91704134, 92303858, 92309761, 99300675, 103303203, 103829439, 104303470, 117553178, 121361401, 124749801, 124800556, 124880071, 124880072, 124880073, 124880074, 124880075, 124880076, 124887017, 125541590, 128580094
|
| Target and Pathway |
| Target(s) |
Voltage-dependent L-type calcium channel subunit alpha-1C |
Target Info |
Activator |
[2]
|
|---|
| Cav1.1 |
Target Info |
Activator |
[3]
|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
Calcium signaling pathway
|
|
cGMP-PKG signaling pathway
|
|
cAMP signaling pathway
|
|
Cardiac muscle contraction
|
|
Adrenergic signaling in cardiomyocytes
|
|
Vascular smooth muscle contraction
|
|
Circadian entrainment
|
|
Long-term potentiation
|
|
Retrograde endocannabinoid signaling
|
|
Glutamatergic synapse
|
|
Cholinergic synapse
|
|
Serotonergic synapse
|
|
GABAergic synapse
|
|
Dopaminergic synapse
|
|
Insulin secretion
|
|
GnRH signaling pathway
|
|
Oxytocin signaling pathway
|
|
Type II diabetes mellitus
|
|
Alzheimer's disease
|
|
Amphetamine addiction
|
|
Hypertrophic cardiomyopathy (HCM)
|
|
Arrhythmogenic right ventricular cardiomyopathy (ARVC)
|
|
Dilated cardiomyopathy
|
|
NetPath Pathway
|
IL2 Signaling Pathway
|
|
PANTHER Pathway
|
Alzheimer disease-amyloid secretase pathway
|
|
Nicotinic acetylcholine receptor signaling pathway
|
|
5HT2 type receptor mediated signaling pathway
|
|
Beta1 adrenergic receptor signaling pathway
|
|
Beta2 adrenergic receptor signaling pathway
|
|
Oxytocin receptor mediated signaling pathway
|
|
Nicotine pharmacodynamics pathway
|
|
PathWhiz Pathway
|
Muscle/Heart Contraction
|
|
Reactome
|
Adrenaline,noradrenaline inhibits insulin secretion
|
|
NCAM1 interactions
|
|
Regulation of insulin secretion
|
|
WikiPathways
|
Calcium Regulation in the Cardiac Cell
|
|
Arrhythmogenic Right Ventricular Cardiomyopathy
|
|
Alzheimers Disease
|
|
NCAM signaling for neurite out-growth
|
|
Integration of energy metabolism
|
|
Nicotine Activity on Chromaffin Cells
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2518). |
|---|
| REF 2 | The calcium channel ligand FPL 64176 enhances L-type but inhibits N-type neuronal calcium currents. Neuropharmacology. 2003 Aug;45(2):281-92. |
|---|
| REF 3 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 528). |
|---|
